Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Daptomycin

Daptomycin

Daptomycin is a lipopeptide antibiotic used to treat complex Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
It acts by binding to the bacterial cell membrane and disrupting its integrity, leading to cell death.
Daptomycin is often used as a last-resort treatment option for severe, life-threating infections that have not responded to other antibiotics.
Researchers can leverage PubCompare.ai's innovative AI-powered tools to streamline their Daptomycin research, easily locate relevant protocols, and identify the most effctive products and approaches.
This can help accelerate the development of new Daptomycin-based treatments and improve research reproducibility.

Most cited protocols related to «Daptomycin»

1
Antimicrobial Susceptibility Testing and MRSA Detection
Cited 10 times
Antimicrobial susceptibility testing was performed using the broth microdilution assay as described by Deutsches Institut für Normung, DIN 58940. [19] Interpretation of the results was done according to the EUCAST standard [20] . The MIC test panel included penicillin G, oxacillin, gentamicin, erythromycin, clindamycin, ciprofloxacin, moxifloxacin, oxytetracycline, cotrimoxazol, rifampicin, fusidic acid, fosfomycin, linezolid, mupirocin, daptomycin, tigecyclin, vancomycin, and teicoplanin. Furthermore all isolates were checked for susceptibility against oxacillin/sulbactam by a tube test as described previously [21] (link).
Test for growth on chromogenic selective agar plates: Colonies grown on blood agar plates after overnight incubation were suspended in 0.9% NaCl solution with a turbidity corresponding to the 0.5 McFarland turbidity standard. This suspension and appropriate dilutions were inoculated in parallel onto sheep blood agar plates (Mueller Hinton agar containing sheep blood, OXOID) and onto chromogenic agar plates from three different manufacturers (chromID™ MRSA, bioMerieux; Brilliance™ MRSA, Oxoid; chromagar™ MRSA, Becton Dickinson). Growth was recorded after overnight incubation at 37±1°C. Efficiency of plating was calculated as the proportion of colony forming units on selective agar plates in comparison to blood agar plates.
Phenotypic test for the expression of PBP2a: The Slidex Staph MRSA test kit from bioMerieux was used as recommended by the manufacturer.
Cuny C., Layer F., Strommenger B, & Witte W. (2011). Rare Occurrence of Methicillin-Resistant Staphylococcus aureus CC130 with a Novel mecA Homologue in Humans in Germany. PLoS ONE, 6(9), e24360.
Publication 2011
Agar azo rubin S Biological Assay Blood BLOOD Ciprofloxacin Clindamycin Daptomycin Erythromycin Fosfomycin Fusidic Acid Gentamicin Linezolid Methicillin-Resistant Staphylococcus aureus Microbicides Moxifloxacin Mupirocin Normal Saline Oxacillin Oxytetracycline Penicillin G Phenotype Rifampin Sheep Staphylococcal Infections Sulbactam Susceptibility, Disease Technique, Dilution Teicoplanin Vancomycin
2
Crowdsourcing and Classroom Curation of Biosynthetic Gene Clusters
Cited 9 times
Since its inception in 2015, MIBiG has provided an online submission form for adding new entries. To submit a new entry, a user starts by requesting a MIBiG accession number. This is done through submitting the product name(s) and the sequence information of the BGC, preferably in the form of a set of coordinates corresponding to the BGC’s position within an NCBI Genbank accession. After the request is approved by MIBiG staff, the workflow subsequently provides an extended entry form where users can input more detailed information. This crowdsourcing, open-for-all approach has garnered 140 new entries since 2015, with contributions coming from various experts all over the world.
Because not all newly characterized BGCs are submitted to the database, we actively complemented this crowdsourcing approach by periodically organizing in-house ‘Annotathons’, where multiple scientists sat together for an entire day to work on MIBiG curation (Supplementary Table S1). This has yielded 702 new entries, and annotation quality improvements for over 600 BGCs.
More recently, we have introduced an additional MIBiG curation process into the classroom environment with the help of a comprehensive and very specific set of guidelines for the students (10 (link),11 (link)). By giving one task to multiple students to work on independently, and later on having an expert (the teacher) to combine and validate the results, we have generated an additional 10 high quality BGC entries, for actinomycin, carbapanem, daptomycin, ebelactone, lipstatin, nocardicin A, obaflourin, oxazolomycin, salinosporamide and tabtoxin. Scaling up this process in the future may allow the annotations of many more important entries, which have remained incomplete, because, e.g. the scientists who have worked on the pathway are no longer active in the field.
Kautsar S.A., Blin K., Shaw S., Navarro-Muñoz J.C., Terlouw B.R., van der Hooft J.J., van Santen J.A., Tracanna V., Suarez Duran H.G., Pascal Andreu V., Selem-Mojica N., Alanjary M., Robinson S.L., Lund G., Epstein S.C., Sisto A.C., Charkoudian L.K., Collemare J., Linington R.G., Weber T, & Medema M.H. (2019). MIBiG 2.0: a repository for biosynthetic gene clusters of known function. Nucleic Acids Research, 48(D1), D454-D458.
Publication 2019
Actinomycin Daptomycin lipstatin nocardicin oxazolomycin Student tabtoxin
3
Real-World Daptomycin Prescribing Patterns and Impact
Cited 8 times
The purpose of this study is to collect real-world data about the non-controlled prescribing use and impact of daptomycin. Therefore, a non-interventional, multicentre, retrospective design was chosen. Investigators were asked to voluntarily include as many patients as available. Patients could be retrospectively included if they were treated with at least one dose of daptomycin and if all relevant information was entered in the case report form (CRF). Patients who received daptomycin as part of a controlled clinical trial were not eligible for inclusion. Investigators at >100 institutions across Europe collected anonymous demographic, antibiotic, microbiological and clinical data from medical records using a standardized CRF and protocol. Argentinean sites were also allowed to participate, as overall enrolment predictions were uncertain and daptomycin had just been approved in that country. Written informed consent that complies with the ICH Good Clinical Practice guideline was obtained if required by the institutional review board or ethics committee and/or local data privacy regulations, and the protocol was approved by the health authority and the institutional review board or ethics committee, as required, in each country. Investigators were trained on the CRF and received written instructions to further guide the collection of patient data. Each patient is uniquely identified in the study by a combination of his/her centre number and patient number. All data are entered on standardized CRFs exclusively according to the investigator's judgement. Data from the CRFs are entered into the study database by certified contract research organization staff working on behalf of the sponsor. After database lock, all available data were distributed to all authors of the manuscript, who take part in scheduled publication committee meetings. All information collected reflected standard practice in each site. There was no intervention or restriction in clinical practice. Patient data can be recorded into this registry after a minimum of 30 days from the end of daptomycin therapy to permit the capture of AEs/serious AEs (SAEs). The CRFs collected the following information: treatment period; demographics; underlying diseases; pregnancy; neutropenia; antimicrobials; use of other antibiotics and statins; renal function; creatine phosphokinase (CPK) concentrations; diagnosis and current infection details; doses of current antibiotic treatment; duration of inpatient and/or outpatient treatment; outcomes; AEs and SAEs occurring between treatment onset and 30 days after last dose of daptomycin; and discharge information. No instructions were provided concerning drug discontinuation, study completion or post-study treatment. However, the reasons for study drug discontinuation, reason for completion of daptomycin treatment and antibiotic use after daptomycin treatment were captured. In cases of multiple infection, investigators entered the type of infection in order of clinical significance (i.e. primary or secondary infection) for which the patient received daptomycin.
In the database, the primary infection was always automatically assigned to the disease of higher hierarchy according to the following predefined severity classification (in order of most to least severe): endocarditis; osteomyelitis; bacteraemia; other [CNS infection, foreign body/prosthetic infection, metastatic abscess, necrotizing fasciitis, necrotizing infection, surgical/non-surgical antibiotic prophylaxis, septic arthritis and urinary tract infection (UTI)/pyelonephritis]; cSSTI; uncomplicated skin and soft tissue infection (uSSTI). This classification was needed to allow for analysis standardization and was based on experts’ and sponsor's judgement taking into consideration clinical prognosis, probability of microbiology eradication and consequences of treatment failure. Safety analysis included all reports of AEs, the severity of which was determined by the investigators. AEs were recorded regardless of their relationship to daptomycin therapy. The overall methodology of this registry, including the definitions mentioned in the following section, is aligned with the CORE registry methodology. It is possible to merge the databases to perform combined or comparative analyses between different regions, as recently published by Gonzalez-Ruiz et al.9
Gonzalez-Ruiz A., Beiras-Fernandez A., Lehmkuhl H., Seaton R.A., Loeffler J, & Chaves R.L. (2011). Clinical experience with daptomycin in Europe: the first 2.5 years. Journal of Antimicrobial Chemotherapy, 66(4), 912-919.
Publication 2011
Abscess Antibiotic Prophylaxis Antibiotics Arthritis, Infectious Bacteremia Care, Ambulatory Central Nervous System Infection Clinical Reasoning Creatine Kinase Daptomycin Diagnosis Endocarditis Ethics Committees Ethics Committees, Research Foreign Bodies Hydroxymethylglutaryl-CoA Reductase Inhibitors Infection Inpatient Kidney Leukopenia Microbicides Necrotizing Fasciitis Operative Surgical Procedures Osteomyelitis Patient Discharge Patients Pharmaceutical Preparations Pregnancy Prognosis Pyelonephritis Safety Secondary Infections Skin Soft Tissue Infection Therapeutics Urinary Tract Infection
4
Antimicrobial Therapy Modification Patterns
Cited 6 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Amox clav Amoxicillin Carbapenems Cefepime Cephalosporins Clindamycin Colistin Condoms Daptomycin Early Therapy Ertapenem Fluoroquinolones Hypersensitivity Infection Inpatient Linezolid Macrolides Metronidazole Microbicides Nafcillin Outpatients pathogenesis Patient Discharge Patients Penicillins Pharmaceutical Preparations Physicians Tigecycline Treatment Protocols Trimethoprim-Sulfamethoxazole Combination Vancomycin Vision X-Rays, Diagnostic
5
Lipid Extraction and Analysis of Lysyl-Phosphatidylglycerol
Cited 5 times
The plasmids and strains constructed in this study are listed in Table S1 and primers are listed in Table S2. Construction of plasmids, growth conditions, alignment and prediction of MprF structure, Western-blot analysis, lipid extraction, and analysis of Lys-PG distribution are described in Text S1.
For detection of Lys-PG appropriate amounts of polar lipid extracts were spotted onto silica 60 F254 HPTLC plates (Merck, Darmstadt, Germany) using a Linomat 5 sample application unit (Camag, Berlin, Germany) and developed with chloroform/methanol/water (65∶25∶4, by vol.) in an automatic developing chamber ADC 2 (Camag, Berlin, Germany). Amino groups or phosphate groups-containing lipids were selectively stained with ninhydrin spray (0.3 g ninhydrin dissolved in 100 ml 1-butanol and 3 ml 100% acetic acid) or molybdenum blue spray (Sigma). Integrated lipid spot intensities of molybdenum blue-stained phospholipids were determined by ImageJ (http://rsbweb.nih.gov/ij/). MIC values of gallidermin, HNP1-3, and LL-37 were determined by diluting bacteria from overnight cultures to an OD600 nm of 0.05 −0.1 in fresh MHB medium (gallidermin) or half-concentrated MHB (HNP1-3 and LL-37) containing serial dilutions of antimicrobial peptides as described recently [45] (link). Gallidermin was kindly provided by Friedrich Götz. HNP1-3 was isolated from human neutrophils and purified by reversed-phase high-performance liquid chromatography (RP-HPLC) as described previously [37] (link). LL-37 was synthesized by solid-phase peptide synthesis and purified by RP-HPLC [46] (link). Susceptibility to daptomycin was determined by epsilometer test (E test) in the presence of CaCl2 according to the manufacturer's advise (AB Biodisk) [47] (link). Differences in bacterial capacity to repulse cationic proteins were determined by comparing binding of the red-coloured cationic protein cytochrome c as described recently [37] (link),[48] (link).
Ernst C.M., Staubitz P., Mishra N.N., Yang S.J., Hornig G., Kalbacher H., Bayer A.S., Kraus D, & Peschel A. (2009). The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion. PLoS Pathogens, 5(11), e1000660.
Publication 2009
Acetic Acid Antimicrobial Peptide Bacteria Binding Proteins Butanols Cations Chloroform Cytochromes c' Daptomycin Epsilometer Test gallidermin Growth Disorders High-Performance Liquid Chromatographies Homo sapiens Hypertensive Nephropathy Lipids Methanol molybdenum blue Neutrophil Ninhydrin Oligonucleotide Primers Phosphates Phospholipids Plasmids Proteins Silicon Dioxide Strains Susceptibility, Disease Technique, Dilution Western Blot

Most recents protocols related to «Daptomycin»

1
Antimicrobial Resistance Profiling of Enterococcus
Minimum inhibitory concentrations (MICs) to ampicillin, gentamicin, vancomycin, teicoplanin, ciprofloxacin, tigecycline, linezolid, daptomycin and quinupristin/dalfopristin were examined by E-test (Liofilchem, Italy). MICs results were interpreted according to the recommendations of The European Committee on Antimicrobial Susceptibility Testing (EUCAST Breakpoint tables for interpretation of MICs and zone diameters, version 11.0, 2021, http://www.eucast.org/clinical_breakpoints/). The Clinical and Laboratory Standards Institute (CLSI) guidelines, 2021, https://clsi.org/standards/ were used to interpret the MICs for daptomycin. The presence of vanABCDMN genes was investigated by colony multiplex PCR assay using the primer sequences and PCR protocol described by Nomura et al. [22 (link)]. Briefly, a modified PCR mix for detection of the investigated genes was applied containing 0.4 µM (each) primer, 200 µM (each) dNTP, 1 U of Taq (Canvax, Spain), 1X reaction buffer, 2.5 mM MgCl2, ultrapure PCR H2O and 10 ng DNA template to a final volume of 20 µL. The PCR thermal conditions consisted of initial denaturation (94 °C for 4 min), followed by 30 cycles of denaturation (94 °C for 30 s), annealing (62 °C for 35 s) and extension (68 °C for 1 min), with a single final extension of 7 min at 68 °C. The amplified PCR products were analyzed by capillary electrophoresis.
Hristova P.M., Nankov V.M., Hristov I.G., Trifonov S.V., Alexandrova A.S, & Hitkova H.Y. (2023). Gut colonization with vancomicyn-resistant enterococci among patients with hematologic malignancies. Gut Pathogens, 15, 12.
Publication 2023
Ampicillin Biological Assay Buffers Ciprofloxacin Clinical Laboratory Services Daptomycin Electrophoresis, Capillary Europeans Genes Genes, vif Gentamicin Linezolid Magnesium Chloride Microbicides Minimum Inhibitory Concentration Multiplex Polymerase Chain Reaction Oligonucleotide Primers quinupristin-dalfopristin Susceptibility, Disease Teicoplanin Tigecycline Vancomycin
2
Antimicrobial Resistance Profiles During COVID-19
The antimicrobial resistance profiles were provided by Phoenix BD automated system (Becton Dickinson Franklin Lakes, NJ, EUA); according to manufacturing protocols, each panel was standardized for Gram-positive and Gram-negative AST profiles comprehending the list below:
Aminoglycoside: Amikacin (AMK), Gentamicin (GEN), Synergism Gentamicin (SGEN), Synergism Streptomycin (SSTP), Tobramycin (TOB); Cephalosporins: Cefepime (FEP), Cefoxitin (FOX), Ceftaroline (CPT), Ceftazidime (CAZ), Ceftazidime + Avibactam (CZA), Ceftriaxone (CRO), Cefuroxime (CXM), Cefazolin (CZ); Quinolones: Ciprofloxacin (CIP), Norfloxacin (NX), Levofloxacin (LVX); Penicillin: Amoxicillin/Clavulanic acid (AMC), Ampicillin (AMP), Ampicillin/Sulbactam (SAM), Oxacillin (OXA), Penicillin (PEN), Piperacillin/Tazobactam (TZP); Carbapenems: Ertapenem (ETP), Imipenem (IPM), Meropenem (MEM); Glycopeptides: Teicoplanin (TEC), Vancomycin (VAN): Macrolide: Erythromycin (ERY), Rifampicin (RIP): Lincosamides: Clindamycin (CLI); Oxazolidinone: Linezolid (LZD); Tetracycline: Tetracycline (TET), Minocycline (MIN); Sulfonamides: Sulfamethoxazole/Trimethoprim (STX); Nitroimidazoles: Nitrofurantoin (NIT); Amphenicol: Chloramphenicol (C); Phosphonate: Fosfomycin (FOS); Glycylcyclines: Tigecycline (TGC); Polypeptide: Colistin (CL); Lipopeptides: Daptomycin (DAP).
The resistance profile was classified as resistant (R), and susceptible (S). Any isolate with resistance to three or more classes of antimicrobial agents was classified as multidrug-resistant (MDR) according to the definition proposed by Magiorakos et al. (2012) (link). Some of the clinical isolates were retrieved at the moment of hospitalization for epidemiological active surveillance and infection control. A total of 256 isolates were included in the study and 196 had the antimicrobial susceptibility test performed (Table 1).
Data for new COVID-19 cases for each month were obtained from the Brazilian Ministry of Health (MS) and the State Health Department of Rio de Janeiro, compiled by Cota (2020) .
The prevalence of bacteria species in pediatric, neonatal-ICU, and gynecology/obstetrics wards during the pandemic period was evaluated. In order to compare these three wards with other hospital wards, a total of 2,551 bacteria isolates were recovered from the HICC-HUAP.
Pinheiro F.R., Rozza-de-Menezes R.E., Blum M.C., Pereira R.F., Rocha J.A., Guedes Pinto M.C., Penna B.A., Riley L.W, & Aguiar-Alves F. (2023). Evaluation of changes in antimicrobial susceptibility in bacteria infecting children and their mothers in pediatric, neonatal-intensive care unit, and gynecology/obstetrics wards of a quaternary referral hospital during the COVID-19 pandemic. Frontiers in Microbiology, 14, 1096223.
Publication 2023
Amikacin Aminoglycosides Amox clav Amphenicol Ampicillin ampicillin-sulbactam avibactam - ceftazidime Bacteria Carbapenems Cefazolin Cefepime Cefoxitin ceftaroline Ceftazidime Ceftriaxone Cefuroxime Cephalosporins Chloramphenicol Ciprofloxacin Clindamycin Colistin COVID 19 Daptomycin Ertapenem Erythromycin Fosfomycin Gentamicin Glycopeptides glycylcycline Hospitalization Imipenem Infant, Newborn Infection Control Levofloxacin Lincosamides Linezolid Lipopeptides Macrolides Meropenem Microbicides Minocycline Nitrofurantoin Nitroimidazoles Norfloxacin Oxacillin Oxazolidinones Pandemics Penicillins Phosphonates Piperacillin-Tazobactam Combination Product Polypeptides Quinolones Rifampin Streptomycin Sulfonamides Susceptibility, Disease Teicoplanin Tetracycline Tigecycline Tobramycin Trimethoprim-Sulfamethoxazole Combination Vancomycin
3
Antibiotic Stewardship for COVID-19 Patients

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Antibiotics Antibiotics, Antitubercular Antimicrobial Stewardship Bacterial Infections Carbapenems COVID 19 Daptomycin Fluoroquinolones Linezolid Microbicides Operative Surgical Procedures Patients Physicians Prescriptions Therapeutics Tigecycline
4
Bacillus subtilis Growth and Transformation
B. subtilis strains were grown routinely on nutrient agar (NA; Oxoid) or in nutrient broth (NB; Oxoid). For some assays, strains were grown in liquid Difco antibiotic medium 3 (Penassay broth [PAB]; Oxoid) and on PAB agar (15 g/L agar; Oxoid). B. subtilis transformations were carried out as previously described using SMM defined minimal medium (71 (link), 72 (link)). B. subtilis cultures were usually incubated at 30°C (overnight), and the next morning, they were diluted and grown at 37°C (unless otherwise specified). Escherichia coli and Staphylococcus aureus strains were incubated at 37°C on NA plates or in Luria-Bertani (LB) medium. PCR, plasmid manipulations, and E. coli transformation were carried out using standard methods. Strains were selected on NA supplemented with ampicillin (100 μg/mL for E. coli), spectinomycin (60 μg/mL), kanamycin (5 μg/mL), phleomycin (1 μg/mL), erythromycin (0.5 μg/mL), chloramphenicol (5 μg/mL), or daptomycin (see below). Various supplements were also used: IPTG (isopropyl-β-d-thiogalactopyranoside) (0.1 or 1 mM), X-Gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside) (100 μg/mL), MgSO4 (between 5 mM and 25 mM as required), and glucose (final concentrations of up to 1%). For NA plates supplemented with 20 mM MgSO4, the concentrations of spectinomycin, kanamycin, and erythromycin were doubled to avoid the growth of false-positive strains. Strains with the pMUTin-his integration were always grown in the presence of erythromycin.
Guyet A., Alofi A, & Daniel R.A. (2023). Insights into the Roles of Lipoteichoic Acids and MprF in Bacillus subtilis. mBio, 14(1), e02667-22.
Publication 2023
5-bromo-4-chloro-3-indolyl beta-galactoside Agar Ampicillin Antibiotics Biological Assay Chloramphenicol Daptomycin Erythromycin Escherichia coli Galactose Glucose Isopropyl Thiogalactoside Kanamycin Nutrients Phleomycins Plasmids Spectinomycin Staphylococcus aureus Strains Sulfate, Magnesium
5
Daptomycin Susceptibility Assays for S. aureus
For the S. aureus samples for LTA Western blotting, cultures were grown as described above, but after growth in LB medium for 3 h, CaCl2 (1.25 mM final concentration) was added to the cultures, which were then divided and grown for an extra hour with or without daptomycin (DAP) (stock at 1 mg/mL) (catalogue number ab141204; Abcam).
For the NA-CaCl2-DAP assays, strains were grown in NB for about 3 h at 37°C (exponential phase) and then normalized to an OD600 of 0.5. Cells (300 μL) were spread onto 25-mL NA plates supplemented with CaCl2 (1.25 mM final concentration). A 0.016- to 256-mg/L daptomycin antimicrobial susceptibility testing strip (Liofilchem) was applied to the surface of the plate. Plates were incubated at 37°C overnight and scanned after 24 h. Images were edited in Fiji (ImageJ). The manufacturer’s guidance was used for the interpretation of growth inhibition.
To monitor strain growth in a plate reader, we used precultures that had been grown in NB (or in LB medium for S. aureus) at 37°C for about 3 h. For each assay, a daptomycin stock at 17.4 mg/mL was used to prepare a fresh DAP stock at 0.1 mg/mL, and this was used to make dilutions of the antibiotic as required in 96-well plates in 100 μL of medium supplemented with CaCl2 (1.25 mM final concentration). Plates were then loaded with 100 μL of cells (diluted in medium-CaCl2 and normalized to the desired OD600). Plates were shaken at 37°C in a Tecan Sunrise plate reader, and the OD600 was measured every 6 min. Conditions were tested in duplicates or triplicates whenever possible. Data were collected using Magellan software (version 7.2). Microsoft Excel was used for analysis and the generation of graphs.
Guyet A., Alofi A, & Daniel R.A. (2023). Insights into the Roles of Lipoteichoic Acids and MprF in Bacillus subtilis. mBio, 14(1), e02667-22.
Publication 2023
Antibiotics Biological Assay Cells Daptomycin Epiphyseal Cartilage Microbicides Psychological Inhibition Staphylococcus aureus Strains Susceptibility, Disease Technique, Dilution

Top products related to «Daptomycin»

1
Daptomycin by Merck Group
Sourced in United States, Germany
Daptomycin is a lipopeptide antibiotic used in the laboratory setting. It functions as a calcium-dependent antibiotic that disrupts bacterial cell membrane integrity, leading to cell death.
2
Vancomycin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Sao Tome and Principe, Spain, India, Switzerland, Belgium, Sweden, Ireland, France, China, Japan, Australia
Vancomycin is a laboratory product manufactured by Merck Group. It is an antibiotic used for the detection and quantification of Vancomycin-resistant enterococci (VRE) in clinical samples.
3
Etest by bioMérieux
Sourced in France, Sweden, United States, Germany, United Kingdom, Denmark, Italy, Australia, Spain, Switzerland, Japan
Etest is a quantitative antimicrobial susceptibility testing (AST) method developed by bioMérieux. It provides minimum inhibitory concentration (MIC) values for specific antimicrobial agents. Etest utilizes a predefined antimicrobial gradient on a plastic strip to determine the MIC of a tested microorganism.
4
Gentamicin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Spain, France, Sao Tome and Principe, Canada, Switzerland, China, India, Japan, Australia, Austria, Brazil, Denmark, Macao, Israel, Ireland, Argentina, Poland, Portugal, Czechia, Belgium
Gentamicin is a laboratory product manufactured by Merck Group. It is an antibiotic used for the detection and identification of Gram-negative bacteria in microbiological analysis and research.
5
Ciprofloxacin by Merck Group
Sourced in United States, Germany, United Kingdom, France, Australia, Italy, Spain, Poland, Switzerland, India, Canada, Sao Tome and Principe, China, Ireland, Czechia, Japan, Macao, Israel, Belgium, Portugal
Ciprofloxacin is a broad-spectrum antibiotic that belongs to the fluoroquinolone class of antimicrobial agents. It is used in the treatment of various bacterial infections. Ciprofloxacin functions by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV, which are essential enzymes for bacterial DNA replication and transcription.
6
Linezolid by Merck Group
Sourced in United States, Germany, Sao Tome and Principe, China, India, Belgium, United Kingdom
Linezolid is a sterile, white to off-white crystalline powder that is soluble in water. It is a synthetic antibacterial agent that inhibits bacterial protein synthesis.
7
Ampicillin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Switzerland, Sao Tome and Principe, Spain, Ireland, India, Italy, Japan, Brazil, Australia, Canada, Macao, Czechia, New Zealand, Belgium, Cameroon, Austria, Israel, Norway, Denmark, Netherlands
Ampicillin is a broad-spectrum antibiotic used in laboratory settings. It is a penicillin-based compound effective against a variety of gram-positive and gram-negative bacteria. Ampicillin functions by inhibiting cell wall synthesis, leading to bacterial cell lysis and death.
8
Oxacillin by Merck Group
Sourced in United States, Germany, Italy, Czechia, United Kingdom, Japan
Oxacillin is a semi-synthetic penicillin antibiotic used in laboratory settings. It is a crystalline powder that is soluble in water and alcohol. Oxacillin is commonly used in microbiological research and testing procedures.
9
Daptomycin by Novartis
Sourced in Switzerland, United States
Daptomycin is a laboratory product used for in-vitro research and testing purposes. It is a cyclic lipopeptide antibiotic that is effective against certain types of bacteria. Daptomycin functions by disrupting the bacterial cell membrane, leading to cell death.
10
Vitek 2 by bioMérieux
Sourced in France, United States, Germany, Italy, United Kingdom, Canada, Poland, Macao
The Vitek 2 is a compact automated microbiology system designed for the identification and antimicrobial susceptibility testing of clinically significant bacteria and yeasts. The system utilizes advanced colorimetric technology to enable rapid and accurate results for clinical decision-making.

More about "Daptomycin"

Daptomycin is a vital lipopeptide antibiotic used to treat severe, life-threatening Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
This powerful medication acts by binding to the bacterial cell membrane and disrupting its integrity, leading to cell death.
Daptomycin is often employed as a last-resort treatment option when other antibiotics, such as Vancomycin, Gentamicin, Ciprofloxacin, Linezolid, Ampicillin, and Oxacillin, have failed to effectively combat the infection.
Researchers can leverage the innovative AI-powered tools provided by PubCompare.ai to streamline their Daptomycin research.
The platform helps researchers easily locate relevant protocols from literature, preprints, and patents, while also providing AI-driven comparisons to identify the most effective protocols and products.
This can greatly accelerate the development of new Daptomycin-based treatments and improve research reproducibility.
Key subtopics related to Daptomycin research include MIC (Minimum Inhibitory Concentration) testing using the Etest method, antimicrobial susceptibility testing using the Vitek 2 system, and the exploration of combination therapies involving Daptomycin and other antibiotics.
By leveraging the power of PubCompare.ai's innovative tools, researchers can streamline their Daptomycin research, optimize their experiments, and ultimately contribute to the advancement of new, more effective treatments for these severe, life-threatening infections.